Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11333089 | 1.00 | KMT2A (0.33) | KMT2AMEN1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL8322347 | 1.00 | KMT2A (0.33) | KMT2AMEN1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL24421695 | 0.98 | KMT2A (0.34) | KMT2AMEN1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL12758229 | 0.80 | RECQL (0.49) | KMT2AMEN1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL12310405 | 0.77 | KMT2A (0.46) | KMT2AMEN1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL14396159 | 0.77 | KMT2A (0.31) | KMT2AMAOB | |
| SCHEMBL14629850 | 0.77 | KMT2A (0.46) | KMT2AMEN1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL13904439 | 0.74 | MEN1 (0.34) | KMT2AMEN1RECQL | |
| SCHEMBL11326731 | 0.74 | — | — | |
| SCHEMBL16634620 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220144769-A1 | COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2022-05-12 | — | — | US | disclosed |
| US-9110243-B2 | Laminate film, optically compensatory film, polarizing plate, and liquid crystal display device | FUJIFILM CORPORATION (JP) | 2015-08-18 | — | — | US | disclosed |
| US-9110243-B2 | Laminate film, optically compensatory film, polarizing plate, and liquid crystal display device | FUJIFILM CORPORATION (JP) | 2015-08-18 | — | — | US | disclosed |
| US-20120251781-A1 | LAMINATE FILM, OPTICALLY COMPENSATORY FILM, POLARIZING PLATE, AND LIQUID CRYSTAL DISPLAY DEVICE | FUJIFILM CORPORATION (JP) | 2012-10-04 | — | — | US | disclosed |
| US-20120251781-A1 | LAMINATE FILM, OPTICALLY COMPENSATORY FILM, POLARIZING PLATE, AND LIQUID CRYSTAL DISPLAY DEVICE | FUJIFILM CORPORATION (JP) | 2012-10-04 | — | — | US | disclosed |
| US-20120140161-A1 | POLYMER FILM, RETARDATION FILM, POLARIZING PLATE, LIQUID CRYSTAL DISPLAY DEVICE AND ULTRAVIOLET ABSORBER | FUJIFILM CORPORATION (JP) | 2012-06-07 | — | — | US | disclosed |
| US-20120140161-A1 | POLYMER FILM, RETARDATION FILM, POLARIZING PLATE, LIQUID CRYSTAL DISPLAY DEVICE AND ULTRAVIOLET ABSORBER | FUJIFILM CORPORATION (JP) | 2012-06-07 | — | — | US | disclosed |
| US-20110311738-A1 | Process of producing cellulose acylate film, cellulose acylate film, polarizing plate liquid crystal display device and optical compensation film | FUJIFILM CORPORATION (JP) | 2011-12-22 | — | — | US | disclosed |
| US-20110311738-A1 | Process of producing cellulose acylate film, cellulose acylate film, polarizing plate liquid crystal display device and optical compensation film | FUJIFILM CORPORATION (JP) | 2011-12-22 | — | — | US | disclosed |
| EP-0638079-B1 | DEAZAAMINOPTERINS FOR TREATMENT OF INFLAMMATION | STANFORD RES INST INT (US) | 1999-12-15 | — | — | EP | disclosed |
| WO-1993022312-A1 | DEAZAAMINOPTERINS FOR TREATMENT OF INFLAMMATION | SRI INTERNATIONAL (US) | 1993-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144769-A1 | COMPOUND | CBR3, SFXN3, CBR1 | KMT2A 2887/4885MEN1 1793/4885ALDH1A1 928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.